ESMO Open

In this large real-world cohort of patients with mCRC, FTD-TPI + bevacizumab was associated with improved PFS and DCR compared with FTD-TPI or regorafenib, with consistent benefit across most molecular subgroups, including KRAS^G12 mutations.

This study provides the longest prospective OS data for palbociclib in WD/DD LPS. CDK4/6 inhibition remains a relevant treatment option, especially for patients unsuitable for cytotoxic therapy. CDH18 expression was associated with clinical outcomes and represents an exploratory biomarker signal that warrants independent validation in future prospective, biomarker-focused studies.

Cisplatin was not associated with a survival advantage over carboplatin when combined with gemcitabine as a first-line treatment of patients with metastatic TNBC, though numerically longer PFS and higher ORR were observed. Differences in safety profiles may help guide individualized treatment decisions.

The safety profile of SG was manageable and consistent with previous studies, with low rates of TEAEs leading to treatment discontinuation or death; some differences in TEAE rates were observed between NA/EU and Asia. This analysis provides further support for SG as a treatment for mBC across multiple patient subgroups.

in vitro/in vivo) tracked via fluorescence imaging/FCM.Tumor tissues underwent scRNA-seq and bioinformatic analysis.Human MPE samples from lung cancer patients yielded autologous MW-TMPs, tested in 3D spheroids and zebrafish PDX models.Results: This method yields more MW-TMPs with lower nucleic acid content than UV-TMPs.MW-TMPs are HMGB1-enriched and potently induce ICD in tumor cells.In lung ade…

Background: Pathologic complete response (pCR) is utilized more frequently as an endpoint in neoadjuvant immunotherapy trials for resectable non-small cell lung cancer (NSCLC).Its utility as a surrogate for long-term survival, however, remains debated.We conducted a systematic review to evaluate the association between pCR and survival outcomes in this setting. Methods:We performed a systematic s…

ETOP Lungscope aims to evaluate the molecular epidemiology of metastatic non-small cell lung (NSCLC) by translational analysis of clinically well-annotated primary resected NSCLC and matched metastases (met).

Background: To assess the performance of an in-house developed AI Large Language Model (LLM) in assisting lung cancer patient management and compare its efficiency and accuracy against manual clinical workflows. Methods:We conducted a retrospective study on 849 consecutive lung cancer patient MDT records form Feb. 2025 to Dec. 2025.Our proprietary AI "Lung Cancer LLM" performed several tasks: rap…

Background: Neoadjuvant chemoimmunotherapy has improved outcomes for patients with resectable non-small cell lung cancer (NSCLC), enhancing survival and reducing recurrence.It is emerging as a new standard of care, although the optimal treatment combination and predictive biomarkers remain under investigation.This study aimed to evaluate and compare the efficacy of neoadjuvant treatment strategie…

Trophoblast cell surface antigen 2 (TROP2) is a recognized therapeutic target in non-small cell lung carcinoma (NSCLC). The normalized membrane ratio (NMR) is a quantitative measure of TROP2 immunohistochemical (IHC) expression generated by the TROP2 (EPR20043) NSCLC RUO (research use only) algorithm under pathologist supervision. NMR has emerged as a potential predictive score for assessing NSCL…